Twenty-year Follow-up of Histocompatibility Leukocyte Antigen-matched Kidney and Bone Marrow Cotransplantation for Multiple Myeloma With End-stage Renal Disease: Lessons Learned

Transplantation
T R SpitzerTatsuo Kawai

Abstract

Specific immune tolerance of transplanted organs in association with either transient or sustained lymphohematopoietic chimerism has been demonstrated in several preclinical animal models and clinically in patients who are full donor chimeras after hematopoietic stem cell transplantation and subsequently received kidney transplants from the same donor. Most recently, tolerance induction has been extended to patients in whom chimerism was intentionally induced at the time of kidney transplantation. Twenty years ago, we reported the first successful histocompatibility leukocyte antigen-matched sibling donor bone marrow and kidney transplant following nonmyeloablative conditioning in a patient with multiple myeloma and end-stage renal disease (ESRD). After 2 decades, she has normal renal function in the absence of ongoing systemic immunosuppressive therapy. Nine patients have subsequently undergone similar treatment for multiple myeloma with ESRD. In the initial patient, hematopoietic chimerism was detectable for only 105 days after the transplant. In subsequent patients, chimerism detection ranged from 49 days to >14 years. Nevertheless, a long remission of the myeloma and long-term immunosuppression-free survival of the kidney a...Continue Reading

References

Jan 1, 1988·Immunology Today·M Sykes, D H Sachs
May 6, 2006·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Marie-Therese RubioMegan Sykes
Jun 27, 2006·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Y FudabaM Sykes
Jan 25, 2008·The New England Journal of Medicine·Tatsuo KawaiDavid H Sachs
May 21, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Leo LuznikEphraim J Fuchs
Jun 8, 2011·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·G AndreolaM Sykes
Jun 15, 2011·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·A B FarrisR B Colvin
May 10, 2013·The New England Journal of Medicine·Tatsuo KawaiUNKNOWN Immune Tolerance Network
Jan 5, 2014·Cold Spring Harbor Perspectives in Medicine·David H SachsMegan Sykes
Jan 30, 2015·Science Translational Medicine·Heather MorrisMegan Sykes
Feb 20, 2015·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·J D ScandlingS Strober
Jul 23, 2016·JCI Insight·Kiyohiko HottaTatsuo Kawai

❮ Previous
Next ❯

Citations

Jan 29, 2020·The Journal of Clinical Investigation·Christian MorathPeter Terness
Aug 8, 2020·Journal of Translational Medicine·Erik J WoodsBrian H Johnstone

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.